Discover how WuXi AppTec used TidesID automation to complete a complex peptide metabolite identification project within 9 working days in this DMPK case study...

Drug discovery is a journey into the unknown, where some of its most meaningful moments come not at the finish line, but along the way — as scientists keep pushing through uncertainty and setbacks...

Antibody-drug conjugates (ADCs) have emerged as one of the most promising therapeutic modalities in oncology. Yet as molecular designs grow increasingly complex, the synthesis and process development of ADCs are becoming increasingly challenging...

In recent years, drug development has increasingly moved toward precisely targeted therapies that can deliver greater therapeutic effects at lower doses. As emerging modalities such as targeted protein degraders and antibody-drug conjugates continue to advance, drug potency is increasing while required doses are decreasing. Although this trend creates opportunities for more effective therapies, it also places safety and quality-control demands on drug development and manufacturing...

September is Muscular Dystrophy Awareness Month. Treatment of Duchenne muscular dystrophy (DMD) illustrates both the clinical urgency and the technical evolution of oligonucleotide therapies. Phosphorodiamidate morpholino oligomers (PMOs) are a key modality for DMD, and conjugation approaches such as peptide PMO conjugates (PPMOs) and antibody oligonucleotide conjugates (AOCs) have improved muscle delivery in recent studies...

In the long journey of novel drug development, time is a critical variable that can determine success or failure. For a company developing an innovative therapy, reaching key milestones at the right time not only can affect the fate of the molecule but also determine how soon patients can gain access to hope and life-saving treatment...